Savara, Inc. · NASDAQ:SVRA
Savara — Investor Presentation (January 2026)
47 slides from Savara's investor presentation, Jan 9, 2026
Slide 1: Corporate Overview January 2026
Corporate Overview January 2026 Developing new therapies for rare respiratory diseases Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement © Savara Inc. All Rights Reserved. Savara Inc. (“Savara” or the “Company”) cautions you that statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by the use of words such as “expect,” “intend,” “pla
Slide 3: Executive Leadership Team
Executive Leadership Team © Savara Inc. All Rights Reserved. 1zxza Matthew Pauls, J.D., M.B.A. Chair & Chief Executive Officer Anne Erickson Chief Business Officer Dave Lowrance Chief Financial & Administrative Officer Rob Lutz, M.B.A. Chief Operating Officer Braden Parker, M.B.A. Chief Commercial O
Slide 4: Autoimmune PAP Overview and Burden of Disease
Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) Overview and Burden of Disease
Slide 5: Autoimmune PAP: Disease of Alveolar Macrophage Dysfunction
Autoimmune PAP: Disease of Alveolar Macrophage Dysfunction © Savara Inc. All Rights Reserved. Alveoli need surfactant to keep from collapsing GM-CSF is critical for alveolar macrophage function and allows for alveolar surfactant homeostasis, structure, function, and host defense NORMAL vs ABNORMAL A
Slide 6: Autoimmune PAP is a Rare, Long-Term, Chronic Lung Disease
Autoimmune PAP is a Rare, Long-Term, Chronic Lung Disease © Savara Inc. All Rights Reserved. Progressive Shortness of Breath With impaired gas exchange, patients may experience shortness of breath At first it occurs upon exertion, but as disease progresses, it can occur even when a person is at rest
Slide 7: A Lung Lavage is an Invasive Procedure
A Lung Lavage is an Invasive Procedure Performed in a Tertiary Center and is Not Standardized © Savara Inc. All Rights Reserved. Sources: 1: Campo, Assessment and Management of PAP in a Reference Center, Orphanet Jour. of Rare Dis., 2013; 2: Campo, Nat. History of PAP Data from Italian Nat. Referenc
Slide 8: Disease Burden: Higher Healthcare Utilization and Comorbidities
© Savara Inc. All Rights Reserved. Disease Burden: Autoimmune PAP Patients Have Significantly Higher Rates of Healthcare Utilization and Comorbidities1 Charlson Comorbidity Index (CCI)* Outpatient/Inpatient visits (~11 outpatient/~2 inpatient per year) Emergency Room Visits (~1 per year) Longer hosp
Slide 9: Karli's Story
“When You can’t Breathe, Nothing Else Matters:” Karli’s Story © Savara Inc. All Rights Reserved. Karli saw 9 specialists before a pulmonologist diagnosed her with autoimmune PAP She wishes her doctors had used the simple blood test to confirm or rule out a diagnosis earlier I would cough until I cou
Slide 10: Disease Burden: Journey of an Autoimmune PAP Patient
Disease Burden: Journey of an Autoimmune PAP Patient1 © Savara Inc. All Rights Reserved. MOLBREEVI* Clinically meaningful positive Phase 3 results that suggest MOLBREEVI may address the pathophysiology of autoimmune PAP Favorable benefit/risk profile Well tolerated BLA submitted to the FDA in Decemb
Slide 11: MOLBREEVI (molgramostim inhalation solution)
MOLBREEVI* *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. (molgramostim inhalation solution)
Slide 12: Investigational Drug-Device Treatment for Autoimmune PAP
© Savara Inc. All Rights Reserved. Once daily 300 µg inhaled MOLBREEVI (inhaled biologic) Proprietary eFlow® Nebulizer System (PARI) Optimized for MOLBREEVI administration Well-established manufacturer of devices used for inhalation therapy 5 FDA approved nebulizers based on eFlow® Technology Savara
Slide 13: Summary of IMPALA-2 Results
Summary of IMPALA-2 Results © Savara Inc. All Rights Reserved. DLco%, hemoglobin-adjusted percent predicted diffusing capacity of the lungs for carbon monoxide; SGRQ, St. Georges Respiratory Questionnaire. 1Statistically significant.2Nominally significant. Change from baseline to Week 24 in DLco% (p
Slide 14: Phase 3 IMPALA-2 Trial Design
Phase 3 IMPALA-2 Trial Design © Savara Inc. All Rights Reserved. PRIMARY ENDPOINT Change from baseline in DLCO at W24 6-Week Screening Period 1: Double-blind (top line) Period 2: Open-label (ongoing, not part of top line results) SECONDARY ENDPOINTS Change from baseline in: DLCO at W48 SGRQ Total Sc
Slide 15: Discontinuations Low; Open Label Participation High
Discontinuations in Double-Blind Period Were Low: 3% Participation in Open Label Period Was High: 100% of Double-Blind Period Completers © Savara Inc. All Rights Reserved. Screened (n=286) Randomized (n=164) MOLBREEVI n=81 Placebo n=83 Ineligible Patients (n=122) Week 48 Completers n=79 (97.5%) Week
Slide 16: Demographics in IMPALA-2 Well-Balanced
Demographics in IMPALA-2 Were Well-Balanced Across Treatment Groups © Savara Inc. All Rights Reserved. MOLBREEVI N=81 Placebo N=83 Age years Mean (SD) 50.8 (13.03) 48.4 (12.69) Sex n (%) Male Female 44 (54.3) 37 (45.7) 54 (65.1) 29 (34.9) Race n (%) White Asian Black or African American Other 38 (46
Slide 17: MOLBREEVI Superior to Placebo on DLCO at W24 and W48
IMPALA-2: MOLBREEVI Superior to PBO on Change from Baseline in DLCO at W24 (primary endpoint) and W48 (secondary endpoint) © Savara Inc. All Rights Reserved. The minimal clinically important difference (MCID) in change in DLCO is 10% in progressive pulmonary fibrosis and 11% in severe COPD.1 MOLBREE
Slide 18: MOLBREEVI Superior on SGRQ Total Score at W24
IMPALA-2: MOLBREEVI Superior to PBO on Change From Baseline in SGRQ Total Score at W24, Favorability Continues Through W48 © Savara Inc. All Rights Reserved. LSM Change from Baseline Between-Group LSM Difference* P-value Week 24 Mol: -11.5 Pbo: -4.9 -6.59 0.0072† Week 48 Mol: -10.7 Pbo: -5.9 -4.87 0
Slide 19: Nominally Significant on SGRQ Activity Score at W24
IMPALA-2: MOLBREEVI Nominally Significant on Change From Baseline in SGRQ Activity Score at W24, Favorability Continues Through W48 © Savara Inc. All Rights Reserved. *Mean change from baseline compared with placebo. P-values are for difference in LSM compared with placebo. †P-value nominally signif
Slide 20: Nominally Significant on Exercise Capacity at W48
IMPALA-2: MOLBREEVI Nominally Significant on Change From Baseline in Exercise Capacity (Peak METs) at W48 © Savara Inc. All Rights Reserved. *Mean change from baseline compared with placebo. P-values are for difference in LSM compared with placebo. †P-value nominally significant: P-value ≤0.05 but d
Slide 21: MOLBREEVI Reduces Pulmonary Surfactant Burden: GGO Score
IMPALA-2 Demonstrated That MOLBREEVI Reduces Pulmonary Surfactant Burden: Ground Glass Opacity Score at W24 © Savara Inc. All Rights Reserved. *P-value based on post-hoc analysis. GGO, ground glass opacity. MOLBREEVI (N=78) Placebo (N=79) p=0.0004* Baseline After 24 weeks on MOLBREEVI
Slide 22: Whole Lung Lavage Permitted as Rescue Therapy
Whole Lung Lavage (WLL) was Permitted as a Rescue Therapy During the IMPALA-2 Trial © Savara Inc. All Rights Reserved. 17 (~10%) patients underwent at least one lung lavage
Slide 23: IMPALA-2 Safety Summary: Well-Tolerated
IMPALA-2 Safety Summary: MOLBREEVI Was Well-Tolerated © Savara Inc. All Rights Reserved. Treatment Emergent Adverse Events MOLBREEVI N=81 n (%) Placebo N=83 n (%) Any 69 (85) 71 (86) Severe 13 (16) 16 (19) Treatment related 20 (25) 16 (19) Serious 14 (17) 20 (24) Not treatment related 13 (16) 20 (24
Slide 24: IMPALA-2 Safety Summary: Most Common Adverse Events
IMPALA-2 Safety Summary: Most Common Adverse Events © Savara Inc. All Rights Reserved. ADVERSE EVENTS IN >10% OF PATIENTS IN ANY TREATMENT ARM DURING DOUBLE-BLIND TREATMENT PERIOD Treatment Emergent Adverse Events MOLBREEVI (N=81) n (%) Placebo (N=83) n (%) Any 69 (85) 71 (86) Most common COVID-19 1
Slide 25: Overview of IMPALA-2 Results
Overview of IMPALA-2 Results: Top Line, DSS, Responder Analyses, and GGO Data © Savara Inc. All Rights Reserved. Measure Timeframe P-Value / Results Pulmonary gas exchange DLCO% Week 24 Week 48 0.0007 0.0008 Disease Severity Score (DSS) Responder Analysis - DLco% Week 24 Week 48 Weeks 24 and 48 0.02
Slide 26: Real-World, Retrospective Outcomes Data
Real-World, Retrospective Outcomes Data Suggest MOLBREEVI Addresses Underlying Pathophysiology of Autoimmune PAP © Savara Inc. All Rights Reserved. Montaño C, Bendstrup E, Rønnov-Jessen I, et al. ERJ Open Res 2025;11:00567-2024. MOLBREEVI treatment led to Improved lung function Decreased disease bur
Slide 27: IMPALA and IMPALA-2 Results Published in NEJM
Results from IMPALA and IMPALA-2 Clinical Trials Were Published in the New England Journal of Medicine © Savara Inc. All Rights Reserved. Published online on 9/2/2020. Published online on 8/21/2025. IMPALA RESULTS IMPALA-2 RESULTS
Slide 28: Regulatory and Intellectual Property
Regulatory and Intellectual Property © Savara Inc. All Rights Reserved.
Slide 29: Planned U.S. and European Regulatory Timeline
Planned U.S. and European Regulatory Timeline © Savara Inc. All Rights Reserved. US Started BLA Rolling Submission EU Completed BLA Submission BLA Resubmitted with Fuji as DS Manufacturer Potential Approval* MAA Submission Potential Approval *Assumes Priority Review is granted by the FDA UK MAA Subm
Slide 30: Regulatory and IP Summary
MOLBREEVI in Autoimmune PAP Regulatory and IP Summary © Savara Inc. All Rights Reserved. Upon Biologics License Application (BLA) approval FDA would grant 12 years marketing exclusivity BIOLOGIC EXCLUSIVITY US Orphan Drug Designation (eligible for 7 years exclusivity) Fast Track Designation Breakthr
Slide 31: Commercial Update
Commercial Update © Savara Inc. All Rights Reserved.
Slide 32: U.S. Autoimmune PAP Addressable Patients
U.S. Autoimmune PAP Addressable Patients © Savara Inc. All Rights Reserved. 26.6 patients / million Kitamura, 2019* Published Autoimmune PAP Epidemiology Literature Coverage: ~300M lives Dataset: Open- and closed-source Data capture: ~100B records Reporting period: 2017-2025 Patient stabilization pe
Slide 33: The U.S. PAP Market is Concentrated
The U.S. PAP Market is Concentrated © Savara Inc. All Rights Reserved. PAP Patient / HCO Heat Map Active PAP Patient Distribution Among HCOs Accounts with 1 patient Accounts with 2-3 patients Accounts with 4+ patients HCO = Healthcare Organization, HCP = Healthcare Provider Veeva Compass Patient cov
Slide 34: Majority of Patients Have Moderate or Severe Disease
Majority of Autoimmune PAP Patients Are Classified with Either Moderate or Severe Disease © Savara Inc. All Rights Reserved. Dr. Bruce Trapnell M.D. Professor of Medicine and Pediatrics, University of Cincinnati College of Medicine, Lead Clinical Investigator of the IMPALA-2 trial Symptomatology Fun
Slide 35: Commercial Planning Advancing Against U.S. Launch Objectives
Commercial Planning Advancing Against U.S. Launch Objectives © Savara Inc. All Rights Reserved. Expand awareness of autoimmune PAP and educate on the importance of early testing Hire and onboard key commercial roles to expand core activities AWARENESS PERSONNEL Build critical capabilities to facilit
Slide 36: Autoimmune PAP Disease State Awareness Campaign
Autoimmune PAP Disease State Awareness Campaign Multi-channel effort across healthcare professionals (HCP) and patients © Savara Inc. All Rights Reserved. HCP DSA Campaign Patient DSA Campaign
Slide 37: aPAP ClearPath Testing Program
aPAP ClearPath Testing Program: No Charge Third-Party Testing Program in the U.S.* © Savara Inc. All Rights Reserved. Created to reduce barriers to GM-CSF autoantibody testing and educate physicians/patients on how testing may be used to help confirm or rule out PAP** * Patients, healthcare professi
Slide 38: Patient Line of Sight and Commercial Field Force
Patient Line of Sight Achieved Line of Sight Goal of ~1,000 Patients by YE 2025 Launch Preparation: Commercial Field Force © Savara Inc. All Rights Reserved. Commercial Field Personnel Head Regional Director Regional Director Regional Director Rare Disease Specialists Rare Disease Specialists Rare D
Slide 39: PANTHERx Rare Pharmacy Selected as Exclusive Specialty Pharmacy
PANTHERx® Rare Pharmacy Selected as Savara’s U.S. Exclusive Specialty Pharmacy (SP) Partner for Distribution of MOLBREEVI © Savara Inc. All Rights Reserved. 8x Top Performing Independent SP Connectivity with Pulmonary Prescribers Relevant Device Experience Specializes in Rare/Orphan Disease Unparall
Slide 40: MyMOLBREEVI: Launch Support in Development
MyMOLBREEVI: Best in Class Launch Support in Development Support programs aim to reduce access barriers for appropriate MOLBREEVI patients post approval © Savara Inc. All Rights Reserved. PATIENT RESOURCES Case management approach Financial assistance Clinical education Insurance services PRESCRIBER
Slide 41: Advancing U.S. Commercial Launch Preparations
MOLBREEVI: Advancing U.S. Commercial Launch Preparations © Savara Inc. All Rights Reserved. ~$400K - $500K per patient per year Pharmacy Benefit Specialty Tier Typical Prior Authorization Criteria Not Concerned About Budget Impact Savara 2024 U.S. payer pricing and reimbursement research: N=10 repre
Slide 42: MOLBREEVI: U.S. Commercial Opportunity
MOLBREEVI: U.S. Commercial Opportunity © Savara Inc. All Rights Reserved. MOLBREEVI Clinically meaningful benefit Strong stakeholder interest Orphan drug pricing potential Chronic dosing Small customer facing footprint Exclusive pharmacy network 12-year biologic exclusivity (U.S.) Biosimilar competi
Slide 43: Europe Market Development is Underway
Europe (EU4+UK) Market Development is Underway © Savara Inc. All Rights Reserved. TREATMENT CENTER MAPPING1 Country Key Centers1 Est. TAM2 Germany 11 ~1,300 UK 25 ~1,104 France 24 ~1,104 Italy 16 ~944 Spain 12 ~784 Total 88 ~5,200 1 Savara 2024 EU4+ UK Primary (N= 6 EU4+ UK Principal Investigators,
Slide 44: Financials
Financials © Savara Inc. All Rights Reserved.
Slide 45: The Company is Well Capitalized
The Company is well capitalized: ~264.4M in cash* Strong investor support with coverage from 8 equity research analysts Financial Highlights © Savara Inc. All Rights Reserved. * Pro forma for cash, cash equivalents, and short-term investments as of 09/30/25, including October 2025 equity offering of
Slide 46: U.S. Autoimmune PAP Market Opportunity is Sizable
U.S. Autoimmune PAP Market Opportunity is Sizable with Blockbuster Potential © Savara Inc. All Rights Reserved. TAM = Total addressable market Current U.S. TAM of autoimmune PAP patients >$2B Potential U.S. Opportunity ~$400K-$500K ~5,500 Orphan rare disease potential pricing power Patents currently
Slide 47: Thank You
A SAVARA Thank You